Evidence map›Paper›PMID 23545991›Full record

Trial reportLeukemia2013

Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial.

M Wang, N Fowler, N Wagner-Bartak, L Feng, J Romaguera, S S Neelapu, F Hagemeister, M Fanale, Y Oki, B Pro and 15 more

2 registry-linked trialsAbstract readClinical Trial, Phase II
PubMed Publisher
In one paragraph

Trial report in Leukemia, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 91 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
91citing papers in PubMed, 4 pooled it
14.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02340936 phase1 / phase2completednot on this map

National, Open-label, Multicentre Phase I-II Study of Combination R-ESHAP With Lenalidomide as Salvage Therapy for Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Candidates to Stem-cell Transplantation

TypeinterventionalSponsorGrupo Español de Linfomas y Transplante Autólogo de Médula ÓseaRan2011 to 2019Enrolled53ConditionsDiffuse Large B-cell LymphomaArmsLR-ESHAP (lenalidomide 5 mg), LR-ESHAP (lenalidomide 10 mg), LR-ESHAP (lenalidomide 15 mg), LR-ESHAP (lenalidomide 20 mg)
NCT02446236 phase1active not recruitingnot on this mapstarted 2015, after this paper: background citation

Phase Ib Dose Finding Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma (MCL)

TypeinterventionalSponsorHackensack Meridian HealthRan2015 to 2026Enrolled27ConditionsMantle Cell LymphomaArmsLenalidomide, Ibrutinib, Rituximab
3 · Its place in the literature

Who cites it

91 citing papers in PubMed, 4 syntheses or guidelines pooled it, 203 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. MogamulizumabHaematologica · 2019
    Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

31 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 2 institutions in 1 country.

M WangDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. miwang@mdanderson.org
N Fowler
N Wagner-Bartak
L Feng
J Romaguera
S S Neelapu
F Hagemeister
M Fanale
Y Oki
B Pro
J Shah
S Thomas
A Younes
C Hosing
L Zhang
K J Newberry
M Desai
N Cheng
M Badillo
M Bejarano
Y Chen
K H Young
R Champlin
L Kwak
L Fayad
The University of Texas MD Anderson Cancer Center · USBaylor College of Medicine · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lenalidomide-rituximab therapy is effective in grade 1-2 follicular and mantle cell lymphoma, but its efficacy in diffuse large B-cell lymphoma (DLBCL), transformed large cell lymphoma (TL) and grade 3 follicular lymphoma (FLG3) is unknown. In this phase II trial, 45 patients with relapsed or refractory DLBCL (n=32), TL (n=9) or FLG3 (n=4) who had received 1-4 prior lines of treatment were given 20 mg oral lenalidomide on days 1-21 of each 28-day cycle, and intravenous rituximab (375 mg/m(2)) weekly during cycle 1. Grade 3/4 hematological toxicities included neutropenia (53%), lymphopenia (40%), thrombocytopenia (33%), leukopenia (27%) and anemia (18%), with a median follow-up time of 29.1 months (range 14.7-52.0 months). Overall response (OR) rate was 33%; median response duration was 10.2 months. Median progression-free survival (PFS) and overall survival (OS) were 3.7 and 10.7 months, respectively. Nine of the 15 responding patients (three partial response (PR), six complete response (CR)) proceeded with stem cell transplantation (SCT) and were censored at the time of transplantation. When data were analyzed without censoring, median PFS remained 3.7 months and response duration increased to 30.9 months. Rituximab plus oral lenalidomide is well tolerated and effective for patients with relapsed/refractory DLBCL and TL. SCT after lenalidomide-rituximab is associated with prolonged response duration.

Indexed as

Administration, OralAdultAgedAged, 80 and overAntibodies, Monoclonal, Murine-DerivedAntineoplastic Combined Chemotherapy ProtocolsDisease ProgressionFemaleHematopoietic Stem Cell TransplantationHumansLenalidomideLymphoma, FollicularLymphoma, Large B-Cell, DiffuseMaleMiddle AgedRecurrenceAntibodies, Monoclonal, Murine-DerivedLenalidomideRituximabThalidomide

Identifiers

PMID23545991
OpenAlexW2126772526

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.